BioPharma

The Engine of Cell Therapy Success: Why Analytical Development Determines Whether Promising Cell Therapies Reach Patients

Yuvraj — Fri, 12 Jun 2026 09:57:32 +0000

How advanced analytical methods, potency assays, and immune profiling are shaping the future of cancer cell therapies Cell therapies have transformed the treatment landscape for patients with cancer and other serious diseases. Innovations such as CAR-T cell therapies have demonstrated remarkable clinical success, offering new treatment options for patients with limited alternatives. While much of […]

The post The Engine of Cell Therapy Success: Why Analytical Development Determines Whether Promising Cell Therapies Reach Patients first appeared on World Pharma Today.

Daewoong and Chime Biologics Partner for Biosimilar Push

Yuvraj — Wed, 10 Jun 2026 12:09:36 +0000

Chime Biologics and Daewoong Pharmaceutical have entered into a strategic collaboration to develop and manufacture a dupilumab biosimilar candidate referencing Dupixent for global markets. The partnership, announced by VMS Group, combines the development and manufacturing capabilities of Chime Biologics with Daewoong Pharmaceutical’s plans to expand its presence in the international biosimilars sector. Through this initiative, […]

The post Daewoong and Chime Biologics Partner for Biosimilar Push first appeared on World Pharma Today.

GNI Group to Acquire Ayumi Pharmaceutical Holdings, Expanding Its Global Biopharmaceutical Position

Yuvraj — Tue, 09 Jun 2026 07:58:55 +0000

GNI Group Co., Ltd. has announced an agreement to acquire 100% of the shares of Ayumi Pharmaceutical Holdings Co., Ltd. from a group of shareholders led by Blackstone, in a transaction that values Ayumi Pharmaceutical Holdings at approximately ¥44.8 billion. The deal will make Ayumi a wholly owned subsidiary of GNI Group and significantly expands […]

The post GNI Group to Acquire Ayumi Pharmaceutical Holdings, Expanding Its Global Biopharmaceutical Position first appeared on World Pharma Today.

Aragen Achieves Daretabart Commercial-scale GMP Production

Yuvraj — Wed, 03 Jun 2026 11:50:39 +0000

Aragen, a global leader in Contract Research, Development, and Manufacturing Organization (CRDMO) services, has announced the successful technology transfer and commercial-scale GMP manufacturing of the first batches of Daretabart, Renaissance Pharma’s lead therapeutic candidate for high-risk neuroblastoma. The milestone was achieved within just nine months, highlighting the efficiency of the collaboration between the two organizations. […]

The post Aragen Achieves Daretabart Commercial-scale GMP Production first appeared on World Pharma Today.

Nestlé and IdB Partner to Bring rCDI Preventive Therapy to Europe

Yuvraj — Mon, 01 Jun 2026 05:48:10 +0000

Nestlé Health Science and IdB Holding have officially announced a VOWST licensing agreement to develop and commercialize the oral therapy in Europe, subject to approval by the European Medicines Agency (EMA). This collaboration aims to expand European patient access to therapies preventing recurrent Clostridioides difficile infection, a severe gastrointestinal condition with limited management options. Currently […]

The post Nestlé and IdB Partner to Bring rCDI Preventive Therapy to Europe first appeared on World Pharma Today.

Recombinant Proteins Driving Biologics Innovation

Yuvraj — Tue, 19 May 2026 13:30:09 +0000

The landscape of modern therapeutic development is being fundamentally reshaped by the precision of recombinant proteins driving biologics innovation. These highly engineered molecules serve as the foundational architecture for initial drug discovery, the creation of sophisticated high-throughput assay development, and the eventual transition into large-scale biologics manufacturing. By utilizing advanced protein expression platforms, the pharmaceutical industry can now produce specific, high-purity proteins that effectively mimic complex natural biological functions with extraordinary accuracy, ensuring that new treatments are both safe and potent for global distribution.

The post Recombinant Proteins Driving Biologics Innovation first appeared on World Pharma Today.

Sun Pharma Organon Buyout Marks Largest Biopharma Deal 2026

Yuvraj — Wed, 29 Apr 2026 11:48:50 +0000

Sun Pharmaceutical Industries has agreed to acquire Organon in a transaction valued at $11.75 billion, creating what the company described as the largest Biopharma Deal recorded in 2026. The agreement brings together two businesses that each generated $6.2 billion in revenue in 2025, effectively doubling Sun Pharma’s scale and strengthening its global position. Already India’s […]

The post Sun Pharma Organon Buyout Marks Largest Biopharma Deal 2026 first appeared on World Pharma Today.

The Hidden Cost of Licensing in Biologic Drug Development

Yuvraj — Fri, 24 Apr 2026 10:47:39 +0000

Royalties, milestone payments, and license fees are often treated as the cost of doing business in biopharma. But for early-stage biotech companies building toward an IND, these obligations can quietly reshape financial models, complicate investor conversations, and create downstream deal terms that are difficult to unwind. Here is what founders need to know.

The post The Hidden Cost of Licensing in Biologic Drug Development first appeared on World Pharma Today.

Trump Order Targets Faster Psychedelic Drug Reviews by FDA

Yuvraj — Thu, 23 Apr 2026 07:08:09 +0000

The Trump administration has introduced a new executive order designed to accelerate Psychedelic Drug Reviews, marking a notable policy move aimed at expediting regulatory pathways for emerging mental health treatments. The directive focuses on advancing FDA evaluation processes for investigational psychedelic therapies, particularly those addressing conditions such as post-traumatic stress disorder (PTSD), anxiety, and depression. […]

The post Trump Order Targets Faster Psychedelic Drug Reviews by FDA first appeared on World Pharma Today.

DeepCyte Raises $1.5M funding to Advance AI Drug Toxicology

Yuvraj — Fri, 10 Apr 2026 11:03:40 +0000

DeepCyte, a techbio company focused on advancing AI Drug Toxicology, has launched with $1.5 million in seed funding. The company is introducing two integrated solutions aimed at helping biopharma teams detect, predict, and explain drug toxicity directly in human cells at single-cell resolution, addressing long-standing gaps in preclinical testing. Drug toxicity remains one of the […]

The post DeepCyte Raises $1.5M funding to Advance AI Drug Toxicology first appeared on World Pharma Today.